Microbial Cell Banking Market By Type of Microbial Cell Banking (Master Cell Bank, Working Cell Bank, End Of Product Cells, Others), By Species Type (Bacteria, Viruses, Cell Lines, Fungi And Yeast, Others); By Testing Type (Culture Viability, Strain Identity, Genetic Stability, Purity Testing, Use Testing, Others); By End-User (Pharmaceutical and Biotechnology Companies, Research Institutions, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
The cell banking concept was introduced by the pharmaceutical industry to find treatments and cures for several chronic ailments. Cell banking is a process of storing cells extracted from different body organ tissues and fluids from specific genomes so that they can be used in the future in manufacturing a medicinal product or for medicinal needs. Stored cells contain characterization details of the cell line which decreases the chances of cross-contamination. Cells such as mammalian cells, avian cells, insect cell lines, microbial cells, yeast cells, and stem cells are some of the common cells that are used for storing in cell banks for multiple purposes. Microbial cell banking is a technique used for the preservation of cells to maintain their cell potency, viability, and recovery. Microbial cell banking is being used in the manufacturing of several biological therapeutics. In general, we can say that the highest number of biological therapeutics are being extracted from microbial cells either by using genetic modification or the natural cell banking way. Many biotechnology and pharmaceutical companies are increasingly looking for taking up full services from global partners so that they can outsource the entire manufacturing process. This improvement is expected to offer lucrative growth opportunities for several players in the global microbial cell banking market. Moreover, there has been a high focus on new emerging markets which are expected to aid in the growth of this market. The healthcare industry has seen a shift from investment in R&D to technology which is adding fuel to the growth of the microbial cell banking market. Developing countries like India have qualified manpower and ample skilled labor at affordable costs, which has further increased the scope for growth in the microbial cell banking market.
The covid-19 pandemic has impacted the health of several individuals worldwide. As per the World Health Organization (WHO), in January 2021 the covid-19 pandemic has infected nearly 2 million individuals, resulting in tremendous stress on healthcare infrastructure globally. Furthermore, the risk of catching an infection has forced millions of individuals around the world to delay important treatment for deadly diseases. However, despite the disappointing setback the global microbial cell banking market is expected to see growth because of an increase in the research activities done by new biopharmaceuticals to meet the unmet needs in the healthcare department.
Microbial cell banking market is growing at a CAGR of 14.45% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Microbial Cell Banking Market Revenue & Forecast, (US$ Million), 2015 – 2029
By Microbial Cell Line Outlook
Basically, there are three major types of microbial cell lines namely working cell banking (MCB), master cell banking (WCB), and End of Product Cells (EOPC). Master cell banking is the preservation process of the preliminary cell substrates which are extracted from initial clones. The purpose of preserving the master cell banks is to control the contamination of diseases, genetic variation, and degradation of cells. Even though working cell banks are extracted from master cell banks for developing biological therapeutics’ last stage there is a vast difference in cell culture components and culture conditions. In working cell banking as well as master cell banking, the maintenance of purity, stability, and identity is the main reason for microbial cell banking’s success. The rise in demand for biological therapeutics is expected to drive the growth of master cell banking (MCB), in the global microbial cell banking market.
By Species Outlook
Based on species type in microbial cell banking market, viruses accounted for the highest market share in 2020. The establishment of viral seed stock which is helpful in manufacturing biological and therapeutical products is driving the growth of this segment. Virus banks ensure that the production of recombinant proteins and vaccines are done using the cells of the viruses stored in the virus bank. There are several contagious and deadly diseases whose cure can be found using the virus-cell banking method.
By End-User Outlook
Microbial cell banking is widely used by pharmaceutical and biotechnology companies as well as research institutions. Among these pharmaceutical and biotechnology companies accounted for the highest market growth in 2020. These companies use cell banks for vaccine production and manufacturing of several biological therapeutics which is driving the growth of this segment.
Regional Outlook
The global microbial cell banking market is segmented into North America, Asia Pacific, Europe, Middle East & Africa, and Latin America. North America is considered as one of the most attractive markets for the global microbial cell banking market owing to the increasing adoption of cell banking along with rising research initiatives among end-users. However, increasing investments and technological advancements in the biopharmaceutical sector in the Asia Pacific region is propelling its growth over the forecast period.
Competitive Landscape
The report provides both, qualitative and quantitative research of microbial cell banking market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, and specification amongst others.
Some of the players operating in the global microbial cell banking market include Ajinomoto Bio-Pharma, Creative Biogene, Molecular Diagnostic Services, Inc., Eurofins Scientific; Vibalogics GmbH; Lonza Group Ltd.; Merck KGaA; Luina Bio; Altogen Labs; Biovian Oy; VGXI, Inc.; ATCC and Charles River Laboratories, Inc.
Global Microbial Cell Banking Market
By Microbial Cell Line
- Master Cell Bank (MCB)
- Working Cell Bank (WCB)
- End of Product Cells (EOPC)
- Others
By Species
- Bacteria
- Viruses
- Cell Lines
- Fungi and Yeast
- Others
By Testing Type
- Culture Viability
- Strain Identity
- Genetic Stability
- Purity Testing
- Use Testing
By End-User
- Pharmaceutical and Biotechnology Companies
- Research Institutions
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Microbial Cell Banking Market
6. Market Synopsis:
Microbial Cell Banking Market
7. Microbial Cell Banking Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Microbial Cell Banking Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Microbial Cell Banking Market
7.6. Porter’s
Five Force Analysis
8. Global Microbial Cell Banking Market Analysis and Forecasts,
2021 – 2029
8.1. Overview
8.1.1. Global
Microbial Cell Banking Market Revenue (US$ Mn)
8.2. Global
Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By Microbial Cell
Line
8.2.1. Master
Cell Bank (MCB)
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2020
8.2.1.3. Market Forecast, 2021 - 2029
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2020
8.2.1.5.1.2. Market
Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2020
8.2.1.5.2.2. Market
Forecast, 2021 - 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2020
8.2.1.5.3.2. Market
Forecast, 2021 - 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2020
8.2.1.5.4.2. Market
Forecast, 2021 - 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2020
8.2.1.5.5.2. Market
Forecast, 2021 - 2029
8.2.2. Working
Cell Bank (WCB)
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2020
8.2.2.3. Market Forecast, 2021 - 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2020
8.2.2.5.1.2. Market
Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2020
8.2.2.5.2.2. Market
Forecast, 2021 - 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2020
8.2.2.5.3.2. Market
Forecast, 2021 - 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2020
8.2.2.5.4.2. Market
Forecast, 2021 - 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2020
8.2.2.5.5.2. Market
Forecast, 2021 - 2029
8.2.3. End of
Product Cells (EOPC)
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2020
8.2.3.3. Market Forecast, 2021 - 2029
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2020
8.2.3.5.1.2. Market
Forecast, 2021 - 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2020
8.2.3.5.2.2. Market
Forecast, 2021 - 2029
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2020
8.2.3.5.3.2. Market
Forecast, 2021 - 2029
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2020
8.2.3.5.4.2. Market
Forecast, 2021 - 2029
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2020
8.2.3.5.5.2. Market
Forecast, 2021 - 2029
8.2.4. Others
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2020
8.2.4.3. Market Forecast, 2021 - 2029
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market
Estimation, 2015 - 2020
8.2.4.5.1.2. Market
Forecast, 2021 - 2029
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 - 2020
8.2.4.5.2.2. Market
Forecast, 2021 - 2029
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market
Estimation, 2015 - 2020
8.2.4.5.3.2. Market
Forecast, 2021 - 2029
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 - 2020
8.2.4.5.4.2. Market
Forecast, 2021 - 2029
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market
Estimation, 2015 - 2020
8.2.4.5.5.2. Market
Forecast, 2021 - 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By
Microbial Cell Line
9. Global Microbial Cell Banking Market Analysis and Forecasts,
2021 – 2029
9.1. Overview
9.2. Global
Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By Species
9.2.1. Bacteria
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2020
9.2.1.3. Market Forecast, 2021 - 2029
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2020
9.2.1.5.1.2. Market
Forecast, 2021 - 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2020
9.2.1.5.2.2. Market
Forecast, 2021 - 2029
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2020
9.2.1.5.3.2. Market
Forecast, 2021 - 2029
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2020
9.2.1.5.4.2. Market
Forecast, 2021 - 2029
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2020
9.2.1.5.5.2. Market
Forecast, 2021 - 2029
9.2.2. Viruses
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2020
9.2.2.3. Market Forecast, 2021 - 2029
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2020
9.2.2.5.1.2. Market
Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2020
9.2.2.5.2.2. Market
Forecast, 2021 - 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2020
9.2.2.5.3.2. Market
Forecast, 2021 - 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2020
9.2.2.5.4.2. Market
Forecast, 2021 - 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2020
9.2.2.5.5.2. Market
Forecast, 2021 - 2029
9.2.3. Cell
Lines
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2020
9.2.3.3. Market Forecast, 2021 - 2029
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2020
9.2.3.5.1.2. Market
Forecast, 2021 - 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2020
9.2.3.5.2.2. Market
Forecast, 2021 - 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2020
9.2.3.5.3.2. Market
Forecast, 2021 - 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2020
9.2.3.5.4.2. Market
Forecast, 2021 - 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2020
9.2.3.5.5.2. Market
Forecast, 2021 - 2029
9.2.4. Fungi
and Yeast
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2020
9.2.4.3. Market Forecast, 2021 - 2029
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2020
9.2.4.5.1.2. Market
Forecast, 2021 - 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2020
9.2.4.5.2.2. Market
Forecast, 2021 - 2029
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2020
9.2.4.5.3.2. Market
Forecast, 2021 - 2029
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2020
9.2.4.5.4.2. Market
Forecast, 2021 - 2029
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2020
9.2.4.5.5.2. Market
Forecast, 2021 - 2029
9.2.5. Others
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2020
9.2.5.3. Market Forecast, 2021 - 2029
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2020
9.2.5.5.1.2. Market
Forecast, 2021 - 2029
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2020
9.2.5.5.2.2. Market
Forecast, 2021 - 2029
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2020
9.2.5.5.3.2. Market
Forecast, 2021 - 2029
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2020
9.2.5.5.4.2. Market
Forecast, 2021 - 2029
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2020
9.2.5.5.5.2. Market
Forecast, 2021 - 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Species
10. Global Microbial Cell Banking Market Analysis and Forecasts,
2021 – 2029
10.1. Overview
10.2. Global
Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By Testing Type
10.2.1. Culture
Viability
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2020
10.2.1.5.1.2. Market
Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2020
10.2.1.5.2.2. Market
Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2020
10.2.1.5.3.2. Market
Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2020
10.2.1.5.4.2. Market
Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2020
10.2.1.5.5.2. Market
Forecast, 2021 - 2029
10.2.2. Strain
Identity
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2020
10.2.2.5.1.2. Market
Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2020
10.2.2.5.2.2. Market
Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2020
10.2.2.5.3.2. Market
Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2020
10.2.2.5.4.2. Market
Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2020
10.2.2.5.5.2. Market
Forecast, 2021 - 2029
10.2.3. Genetic
Stability
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2020
10.2.3.5.1.2. Market
Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2020
10.2.3.5.2.2. Market
Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2020
10.2.3.5.3.2. Market
Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2020
10.2.3.5.4.2. Market
Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2020
10.2.3.5.5.2. Market
Forecast, 2021 - 2029
10.2.4. Purity
Testing
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2020
10.2.4.3. Market Forecast, 2021 - 2029
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2020
10.2.4.5.1.2. Market
Forecast, 2021 - 2029
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2020
10.2.4.5.2.2. Market
Forecast, 2021 - 2029
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2020
10.2.4.5.3.2. Market
Forecast, 2021 - 2029
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2020
10.2.4.5.4.2. Market
Forecast, 2021 - 2029
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2020
10.2.4.5.5.2. Market
Forecast, 2021 - 2029
10.2.5. Use
Testing
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 - 2020
10.2.5.3. Market Forecast, 2021 - 2029
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market
Estimation, 2015 - 2020
10.2.5.5.1.2. Market
Forecast, 2021 - 2029
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 - 2020
10.2.5.5.2.2. Market
Forecast, 2021 - 2029
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market
Estimation, 2015 - 2020
10.2.5.5.3.2. Market
Forecast, 2021 - 2029
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 - 2020
10.2.5.5.4.2. Market
Forecast, 2021 - 2029
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market
Estimation, 2015 - 2020
10.2.5.5.5.2. Market
Forecast, 2021 - 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By
Testing Type
11. Global Microbial Cell Banking Market Analysis and Forecasts,
2021 – 2029
11.1. Overview
11.2. Global
Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By End User
11.2.1. Pharmaceutical
and Biotechnology Companies
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2020
11.2.1.3. Market Forecast, 2021 - 2029
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 - 2020
11.2.1.5.1.2. Market
Forecast, 2021 - 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 - 2020
11.2.1.5.2.2. Market
Forecast, 2021 - 2029
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 - 2020
11.2.1.5.3.2. Market
Forecast, 2021 - 2029
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 - 2020
11.2.1.5.4.2. Market
Forecast, 2021 - 2029
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 - 2020
11.2.1.5.5.2. Market
Forecast, 2021 - 2029
11.2.2. Research
Institutions
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2020
11.2.2.3. Market Forecast, 2021 - 2029
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 - 2020
11.2.2.5.1.2. Market
Forecast, 2021 - 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 - 2020
11.2.2.5.2.2. Market
Forecast, 2021 - 2029
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 - 2020
11.2.2.5.3.2. Market
Forecast, 2021 - 2029
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 - 2020
11.2.2.5.4.2. Market
Forecast, 2021 - 2029
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 - 2020
11.2.2.5.5.2. Market
Forecast, 2021 - 2029
11.2.3. Others
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 - 2020
11.2.3.3. Market Forecast, 2021 - 2029
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 - 2020
11.2.3.5.1.2. Market
Forecast, 2021 - 2029
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 - 2020
11.2.3.5.2.2. Market
Forecast, 2021 - 2029
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 - 2020
11.2.3.5.3.2. Market
Forecast, 2021 - 2029
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 - 2020
11.2.3.5.4.2. Market
Forecast, 2021 - 2029
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 - 2020
11.2.3.5.5.2. Market
Forecast, 2021 - 2029
11.3. Key
Segment for Channeling Investments
11.3.1. By End
User
12. North America Microbial Cell Banking Market Analysis and
Forecasts, 2021 - 2029
12.1. Overview
12.1.1. North
America Microbial Cell Banking Market Revenue (US$ Mn)
12.2. North
America Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Microbial Cell Line
12.2.1. Master
Cell Bank (MCB)
12.2.2. Working
Cell Bank (WCB)
12.2.3. End of
Product Cells (EOPC)
12.2.4. Others
12.3. North
America Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Species
12.3.1. Bacteria
12.3.2. Viruses
12.3.3. Cell
Lines
12.3.4. Fungi
and Yeast
12.3.5. Others
12.4. North
America Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Testing Type
12.4.1. Culture
Viability
12.4.2. Strain
Identity
12.4.3. Genetic
Stability
12.4.4. Purity
Testing
12.4.5. Use
Testing
12.5. North
America Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By End User
12.5.1. Pharmaceutical
and Biotechnology Companies
12.5.2. Research
Institutions
12.5.3. Others
12.6. North
America Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Country
12.6.1. U.S
12.6.1.1. U.S Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
12.6.1.1.1. Master Cell Bank (MCB)
12.6.1.1.2. Working Cell Bank (WCB)
12.6.1.1.3. End of Product Cells (EOPC)
12.6.1.1.4. Others
12.6.1.2. U.S Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
12.6.1.2.1. Bacteria
12.6.1.2.2. Viruses
12.6.1.2.3. Cell Lines
12.6.1.2.4. Fungi and Yeast
12.6.1.2.5. Others
12.6.1.3. U.S Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
12.6.1.3.1. Culture Viability
12.6.1.3.2. Strain Identity
12.6.1.3.3. Genetic Stability
12.6.1.3.4. Purity Testing
12.6.1.3.5. Use Testing
12.6.1.4. U.S Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
12.6.1.4.1. Pharmaceutical and Biotechnology Companies
12.6.1.4.2. Research Institutions
12.6.1.4.3. Others
12.6.2. Canada
12.6.2.1. Canada Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
12.6.2.1.1. Master Cell Bank (MCB)
12.6.2.1.2. Working Cell Bank (WCB)
12.6.2.1.3. End of Product Cells (EOPC)
12.6.2.1.4. Others
12.6.2.2. Canada Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
12.6.2.2.1. Bacteria
12.6.2.2.2. Viruses
12.6.2.2.3. Cell Lines
12.6.2.2.4. Fungi and Yeast
12.6.2.2.5. Others
12.6.2.3. Canada Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
12.6.2.3.1. Culture Viability
12.6.2.3.2. Strain Identity
12.6.2.3.3. Genetic Stability
12.6.2.3.4. Purity Testing
12.6.2.3.5. Use Testing
12.6.2.4. Canada Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
12.6.2.4.1. Pharmaceutical and Biotechnology Companies
12.6.2.4.2. Research Institutions
12.6.2.4.3. Others
12.6.3. Mexico
12.6.3.1. Mexico Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
12.6.3.1.1. Master Cell Bank (MCB)
12.6.3.1.2. Working Cell Bank (WCB)
12.6.3.1.3. End of Product Cells (EOPC)
12.6.3.1.4. Others
12.6.3.2. Mexico Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
12.6.3.2.1. Bacteria
12.6.3.2.2. Viruses
12.6.3.2.3. Cell Lines
12.6.3.2.4. Fungi and Yeast
12.6.3.2.5. Others
12.6.3.3. Mexico Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
12.6.3.3.1. Culture Viability
12.6.3.3.2. Strain Identity
12.6.3.3.3. Genetic Stability
12.6.3.3.4. Purity Testing
12.6.3.3.5. Use Testing
12.6.3.4. Mexico Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
12.6.3.4.1. Pharmaceutical and Biotechnology Companies
12.6.3.4.2. Research Institutions
12.6.3.4.3. Others
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Microbial Cell Banking Market Revenue
(US$ Mn) and Forecasts, By Microbial Cell Line
12.6.4.1.1. Master Cell Bank (MCB)
12.6.4.1.2. Working Cell Bank (WCB)
12.6.4.1.3. End of Product Cells (EOPC)
12.6.4.1.4. Others
12.6.4.2. Rest of North America Microbial Cell Banking Market Revenue
(US$ Mn) and Forecasts, By Species
12.6.4.2.1. Bacteria
12.6.4.2.2. Viruses
12.6.4.2.3. Cell Lines
12.6.4.2.4. Fungi and Yeast
12.6.4.2.5. Others
12.6.4.3. Rest of North America Microbial Cell Banking Market Revenue
(US$ Mn) and Forecasts, By Testing Type
12.6.4.3.1. Culture Viability
12.6.4.3.2. Strain Identity
12.6.4.3.3. Genetic Stability
12.6.4.3.4. Purity Testing
12.6.4.3.5. Use Testing
12.6.4.4. Rest of North America Microbial Cell Banking Market Revenue
(US$ Mn) and Forecasts, By End User
12.6.4.4.1. Pharmaceutical and Biotechnology Companies
12.6.4.4.2. Research Institutions
12.6.4.4.3. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Microbial Cell Line
12.7.3. By
Species
12.7.4. By
Testing Type
12.7.5. By End
User
13. Europe Microbial Cell Banking Market Analysis and Forecasts,
2021 - 2029
13.1. Overview
13.1.1. Europe
Microbial Cell Banking Market Revenue (US$ Mn)
13.2. Europe
Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By Microbial Cell
Line
13.2.1. Master
Cell Bank (MCB)
13.2.2. Working
Cell Bank (WCB)
13.2.3. End of
Product Cells (EOPC)
13.2.4. Others
13.3. Europe
Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By Species
13.3.1. Bacteria
13.3.2. Viruses
13.3.3. Cell
Lines
13.3.4. Fungi
and Yeast
13.3.5. Others
13.4. Europe
Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By Testing Type
13.4.1. Culture
Viability
13.4.2. Strain
Identity
13.4.3. Genetic
Stability
13.4.4. Purity
Testing
13.4.5. Use
Testing
13.5. Europe
Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By End User
13.5.1. Pharmaceutical
and Biotechnology Companies
13.5.2. Research
Institutions
13.5.3. Others
13.6. Europe
Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
13.6.1.1.1. Master Cell Bank (MCB)
13.6.1.1.2. Working Cell Bank (WCB)
13.6.1.1.3. End of Product Cells (EOPC)
13.6.1.1.4. Others
13.6.1.2. France Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
13.6.1.2.1. Bacteria
13.6.1.2.2. Viruses
13.6.1.2.3. Cell Lines
13.6.1.2.4. Fungi and Yeast
13.6.1.2.5. Others
13.6.1.3. France Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
13.6.1.3.1. Culture Viability
13.6.1.3.2. Strain Identity
13.6.1.3.3. Genetic Stability
13.6.1.3.4. Purity Testing
13.6.1.3.5. Use Testing
13.6.1.4. France Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
13.6.1.4.1. Pharmaceutical and Biotechnology Companies
13.6.1.4.2. Research Institutions
13.6.1.4.3. Others
13.6.2. The UK
13.6.2.1. The UK Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
13.6.2.1.1. Master Cell Bank (MCB)
13.6.2.1.2. Working Cell Bank (WCB)
13.6.2.1.3. End of Product Cells (EOPC)
13.6.2.1.4. Others
13.6.2.2. The UK Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
13.6.2.2.1. Bacteria
13.6.2.2.2. Viruses
13.6.2.2.3. Cell Lines
13.6.2.2.4. Fungi and Yeast
13.6.2.2.5. Others
13.6.2.3. The UK Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
13.6.2.3.1. Culture Viability
13.6.2.3.2. Strain Identity
13.6.2.3.3. Genetic Stability
13.6.2.3.4. Purity Testing
13.6.2.3.5. Use Testing
13.6.2.4. The UK Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
13.6.2.4.1. Pharmaceutical and Biotechnology Companies
13.6.2.4.2. Research Institutions
13.6.2.4.3. Others
13.6.3. Spain
13.6.3.1. Spain Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
13.6.3.1.1. Master Cell Bank (MCB)
13.6.3.1.2. Working Cell Bank (WCB)
13.6.3.1.3. End of Product Cells (EOPC)
13.6.3.1.4. Others
13.6.3.2. Spain Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
13.6.3.2.1. Bacteria
13.6.3.2.2. Viruses
13.6.3.2.3. Cell Lines
13.6.3.2.4. Fungi and Yeast
13.6.3.2.5. Others
13.6.3.3. Spain Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
13.6.3.3.1. Culture Viability
13.6.3.3.2. Strain Identity
13.6.3.3.3. Genetic Stability
13.6.3.3.4. Purity Testing
13.6.3.3.5. Use Testing
13.6.3.4. Spain Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
13.6.3.4.1. Pharmaceutical and Biotechnology Companies
13.6.3.4.2. Research Institutions
13.6.3.4.3. Others
13.6.4. Germany
13.6.4.1. Germany Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
13.6.4.1.1. Master Cell Bank (MCB)
13.6.4.1.2. Working Cell Bank (WCB)
13.6.4.1.3. End of Product Cells (EOPC)
13.6.4.1.4. Others
13.6.4.2. Germany Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
13.6.4.2.1. Bacteria
13.6.4.2.2. Viruses
13.6.4.2.3. Cell Lines
13.6.4.2.4. Fungi and Yeast
13.6.4.2.5. Others
13.6.4.3. Germany Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
13.6.4.3.1. Culture Viability
13.6.4.3.2. Strain Identity
13.6.4.3.3. Genetic Stability
13.6.4.3.4. Purity Testing
13.6.4.3.5. Use Testing
13.6.4.4. Germany Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
13.6.4.4.1. Pharmaceutical and Biotechnology Companies
13.6.4.4.2. Research Institutions
13.6.4.4.3. Others
13.6.5. Italy
13.6.5.1. Italy Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
13.6.5.1.1. Master Cell Bank (MCB)
13.6.5.1.2. Working Cell Bank (WCB)
13.6.5.1.3. End of Product Cells (EOPC)
13.6.5.1.4. Others
13.6.5.2. Italy Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
13.6.5.2.1. Bacteria
13.6.5.2.2. Viruses
13.6.5.2.3. Cell Lines
13.6.5.2.4. Fungi and Yeast
13.6.5.2.5. Others
13.6.5.3. Italy Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
13.6.5.3.1. Culture Viability
13.6.5.3.2. Strain Identity
13.6.5.3.3. Genetic Stability
13.6.5.3.4. Purity Testing
13.6.5.3.5. Use Testing
13.6.5.4. Italy Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
13.6.5.4.1. Pharmaceutical and Biotechnology Companies
13.6.5.4.2. Research Institutions
13.6.5.4.3. Others
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Microbial Cell Banking Market Revenue (US$
Mn) and Forecasts, By Microbial Cell Line
13.6.6.1.1. Master Cell Bank (MCB)
13.6.6.1.2. Working Cell Bank (WCB)
13.6.6.1.3. End of Product Cells (EOPC)
13.6.6.1.4. Others
13.6.6.2. Nordic Countries Microbial Cell Banking Market Revenue (US$
Mn) and Forecasts, By Species
13.6.6.2.1. Bacteria
13.6.6.2.2. Viruses
13.6.6.2.3. Cell Lines
13.6.6.2.4. Fungi and Yeast
13.6.6.2.5. Others
13.6.6.3. Nordic Countries Microbial Cell Banking Market Revenue (US$
Mn) and Forecasts, By Testing Type
13.6.6.3.1. Culture Viability
13.6.6.3.2. Strain Identity
13.6.6.3.3. Genetic Stability
13.6.6.3.4. Purity Testing
13.6.6.3.5. Use Testing
13.6.6.4. Nordic Countries Microbial Cell Banking Market Revenue (US$
Mn) and Forecasts, By End User
13.6.6.4.1. Pharmaceutical and Biotechnology Companies
13.6.6.4.2. Research Institutions
13.6.6.4.3. Others
13.6.6.5. Nordic Countries Microbial Cell Banking Market Revenue (US$
Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Microbial Cell Line
13.6.7.1.1. Master Cell Bank (MCB)
13.6.7.1.2. Working Cell Bank (WCB)
13.6.7.1.3. End of Product Cells (EOPC)
13.6.7.1.4. Others
13.6.7.2. Benelux Union Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Species
13.6.7.2.1. Bacteria
13.6.7.2.2. Viruses
13.6.7.2.3. Cell Lines
13.6.7.2.4. Fungi and Yeast
13.6.7.2.5. Others
13.6.7.3. Benelux Union Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Testing Type
13.6.7.3.1. Culture Viability
13.6.7.3.2. Strain Identity
13.6.7.3.3. Genetic Stability
13.6.7.3.4. Purity Testing
13.6.7.3.5. Use Testing
13.6.7.4. Benelux Union Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By End User
13.6.7.4.1. Pharmaceutical and Biotechnology Companies
13.6.7.4.2. Research Institutions
13.6.7.4.3. Others
13.6.7.5. Benelux Union Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Microbial Cell Line
13.6.8.1.1. Master Cell Bank (MCB)
13.6.8.1.2. Working Cell Bank (WCB)
13.6.8.1.3. End of Product Cells (EOPC)
13.6.8.1.4. Others
13.6.8.2. Rest of Europe Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Species
13.6.8.2.1. Bacteria
13.6.8.2.2. Viruses
13.6.8.2.3. Cell Lines
13.6.8.2.4. Fungi and Yeast
13.6.8.2.5. Others
13.6.8.3. Rest of Europe Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Testing Type
13.6.8.3.1. Culture Viability
13.6.8.3.2. Strain Identity
13.6.8.3.3. Genetic Stability
13.6.8.3.4. Purity Testing
13.6.8.3.5. Use Testing
13.6.8.4. Rest of Europe Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By End User
13.6.8.4.1. Pharmaceutical and Biotechnology Companies
13.6.8.4.2. Research Institutions
13.6.8.4.3. Others
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By
Microbial Cell Line
13.7.3. By
Species
13.7.4. By
Testing Type
13.7.5. By End
User
14. Asia Pacific Microbial Cell Banking Market Analysis and
Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Asia Pacific
Microbial Cell Banking Market Revenue (US$ Mn)
14.2. Asia
Pacific Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Microbial Cell Line
14.2.1. Master
Cell Bank (MCB)
14.2.2. Working
Cell Bank (WCB)
14.2.3. End of
Product Cells (EOPC)
14.2.4. Others
14.3. Asia
Pacific Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Species
14.3.1. Bacteria
14.3.2. Viruses
14.3.3. Cell
Lines
14.3.4. Fungi
and Yeast
14.3.5. Others
14.4. Asia
Pacific Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Testing Type
14.4.1. Culture
Viability
14.4.2. Strain
Identity
14.4.3. Genetic
Stability
14.4.4. Purity
Testing
14.4.5. Use
Testing
14.5. Asia
Pacific Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By End
User
14.5.1. Pharmaceutical
and Biotechnology Companies
14.5.2. Research
Institutions
14.5.3. Others
14.6. Asia
Pacific Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.1. China
14.6.1.1. China Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
14.6.1.1.1. Master Cell Bank (MCB)
14.6.1.1.2. Working Cell Bank (WCB)
14.6.1.1.3. End of Product Cells (EOPC)
14.6.1.1.4. Others
14.6.1.2. China Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
14.6.1.2.1. Bacteria
14.6.1.2.2. Viruses
14.6.1.2.3. Cell Lines
14.6.1.2.4. Fungi and Yeast
14.6.1.2.5. Others
14.6.1.3. China Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
14.6.1.3.1. Culture Viability
14.6.1.3.2. Strain Identity
14.6.1.3.3. Genetic Stability
14.6.1.3.4. Purity Testing
14.6.1.3.5. Use Testing
14.6.1.4. China Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
14.6.1.4.1. Pharmaceutical and Biotechnology Companies
14.6.1.4.2. Research Institutions
14.6.1.4.3. Others
14.6.2. Japan
14.6.2.1. Japan Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
14.6.2.1.1. Master Cell Bank (MCB)
14.6.2.1.2. Working Cell Bank (WCB)
14.6.2.1.3. End of Product Cells (EOPC)
14.6.2.1.4. Others
14.6.2.2. Japan Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
14.6.2.2.1. Bacteria
14.6.2.2.2. Viruses
14.6.2.2.3. Cell Lines
14.6.2.2.4. Fungi and Yeast
14.6.2.2.5. Others
14.6.2.3. Japan Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
14.6.2.3.1. Culture Viability
14.6.2.3.2. Strain Identity
14.6.2.3.3. Genetic Stability
14.6.2.3.4. Purity Testing
14.6.2.3.5. Use Testing
14.6.2.4. Japan Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
14.6.2.4.1. Pharmaceutical and Biotechnology Companies
14.6.2.4.2. Research Institutions
14.6.2.4.3. Others
14.6.3. India
14.6.3.1. India Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
14.6.3.1.1. Master Cell Bank (MCB)
14.6.3.1.2. Working Cell Bank (WCB)
14.6.3.1.3. End of Product Cells (EOPC)
14.6.3.1.4. Others
14.6.3.2. India Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
14.6.3.2.1. Bacteria
14.6.3.2.2. Viruses
14.6.3.2.3. Cell Lines
14.6.3.2.4. Fungi and Yeast
14.6.3.2.5. Others
14.6.3.3. India Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
14.6.3.3.1. Culture Viability
14.6.3.3.2. Strain Identity
14.6.3.3.3. Genetic Stability
14.6.3.3.4. Purity Testing
14.6.3.3.5. Use Testing
14.6.3.4. India Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
14.6.3.4.1. Pharmaceutical and Biotechnology Companies
14.6.3.4.2. Research Institutions
14.6.3.4.3. Others
14.6.4. New
Zealand
14.6.4.1. New Zealand Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
14.6.4.1.1. Master Cell Bank (MCB)
14.6.4.1.2. Working Cell Bank (WCB)
14.6.4.1.3. End of Product Cells (EOPC)
14.6.4.1.4. Others
14.6.4.2. New Zealand Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
14.6.4.2.1. Bacteria
14.6.4.2.2. Viruses
14.6.4.2.3. Cell Lines
14.6.4.2.4. Fungi and Yeast
14.6.4.2.5. Others
14.6.4.3. New Zealand Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
14.6.4.3.1. Culture Viability
14.6.4.3.2. Strain Identity
14.6.4.3.3. Genetic Stability
14.6.4.3.4. Purity Testing
14.6.4.3.5. Use Testing
14.6.4.4. New Zealand Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
14.6.4.4.1. Pharmaceutical and Biotechnology Companies
14.6.4.4.2. Research Institutions
14.6.4.4.3. Others
14.6.5. Australia
14.6.5.1. Australia Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
14.6.5.1.1. Master Cell Bank (MCB)
14.6.5.1.2. Working Cell Bank (WCB)
14.6.5.1.3. End of Product Cells (EOPC)
14.6.5.1.4. Others
14.6.5.2. Australia Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
14.6.5.2.1. Bacteria
14.6.5.2.2. Viruses
14.6.5.2.3. Cell Lines
14.6.5.2.4. Fungi and Yeast
14.6.5.2.5. Others
14.6.5.3. Australia Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
14.6.5.3.1. Culture Viability
14.6.5.3.2. Strain Identity
14.6.5.3.3. Genetic Stability
14.6.5.3.4. Purity Testing
14.6.5.3.5. Use Testing
14.6.5.4. Australia Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
14.6.5.4.1. Pharmaceutical and Biotechnology Companies
14.6.5.4.2. Research Institutions
14.6.5.4.3. Others
14.6.6. South
Korea
14.6.6.1. South Korea Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
14.6.6.1.1. Master Cell Bank (MCB)
14.6.6.1.2. Working Cell Bank (WCB)
14.6.6.1.3. End of Product Cells (EOPC)
14.6.6.1.4. Others
14.6.6.2. South Korea Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
14.6.6.2.1. Bacteria
14.6.6.2.2. Viruses
14.6.6.2.3. Cell Lines
14.6.6.2.4. Fungi and Yeast
14.6.6.2.5. Others
14.6.6.3. South Korea Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
14.6.6.3.1. Culture Viability
14.6.6.3.2. Strain Identity
14.6.6.3.3. Genetic Stability
14.6.6.3.4. Purity Testing
14.6.6.3.5. Use Testing
14.6.6.4. South Korea Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
14.6.6.4.1. Pharmaceutical and Biotechnology Companies
14.6.6.4.2. Research Institutions
14.6.6.4.3. Others
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Microbial Cell Line
14.6.7.1.1. Master Cell Bank (MCB)
14.6.7.1.2. Working Cell Bank (WCB)
14.6.7.1.3. End of Product Cells (EOPC)
14.6.7.1.4. Others
14.6.7.2. Southeast Asia Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Species
14.6.7.2.1. Bacteria
14.6.7.2.2. Viruses
14.6.7.2.3. Cell Lines
14.6.7.2.4. Fungi and Yeast
14.6.7.2.5. Others
14.6.7.3. Southeast Asia Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Testing Type
14.6.7.3.1. Culture Viability
14.6.7.3.2. Strain Identity
14.6.7.3.3. Genetic Stability
14.6.7.3.4. Purity Testing
14.6.7.3.5. Use Testing
14.6.7.4. Southeast Asia Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By End User
14.6.7.4.1. Pharmaceutical and Biotechnology Companies
14.6.7.4.2. Research Institutions
14.6.7.4.3. Others
14.6.7.5. Southeast Asia Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Microbial Cell Banking Market Revenue
(US$ Mn) and Forecasts, By Microbial Cell Line
14.6.8.1.1. Master Cell Bank (MCB)
14.6.8.1.2. Working Cell Bank (WCB)
14.6.8.1.3. End of Product Cells (EOPC)
14.6.8.1.4. Others
14.6.8.2. Rest of Asia Pacific Microbial Cell Banking Market Revenue
(US$ Mn) and Forecasts, By Species
14.6.8.2.1. Bacteria
14.6.8.2.2. Viruses
14.6.8.2.3. Cell Lines
14.6.8.2.4. Fungi and Yeast
14.6.8.2.5. Others
14.6.8.3. Rest of Asia Pacific Microbial Cell Banking Market Revenue
(US$ Mn) and Forecasts, By Testing Type
14.6.8.3.1. Culture Viability
14.6.8.3.2. Strain Identity
14.6.8.3.3. Genetic Stability
14.6.8.3.4. Purity Testing
14.6.8.3.5. Use Testing
14.6.8.4. Rest of Asia Pacific Microbial Cell Banking Market Revenue
(US$ Mn) and Forecasts, By End User
14.6.8.4.1. Pharmaceutical and Biotechnology Companies
14.6.8.4.2. Research Institutions
14.6.8.4.3. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Microbial Cell Line
14.7.3. By
Species
14.7.4. By
Testing Type
14.7.5. By End
User
15. Middle East and Africa Microbial Cell Banking Market Analysis
and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Middle
East and Africa Microbial Cell Banking Market Revenue (US$ Mn)
15.2. Middle
East and Africa Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Microbial Cell Line
15.2.1. Master
Cell Bank (MCB)
15.2.2. Working
Cell Bank (WCB)
15.2.3. End of
Product Cells (EOPC)
15.2.4. Others
15.3. Middle
East and Africa Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Species
15.3.1. Bacteria
15.3.2. Viruses
15.3.3. Cell
Lines
15.3.4. Fungi
and Yeast
15.3.5. Others
15.4. Middle
East and Africa Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Testing Type
15.4.1. Culture
Viability
15.4.2. Strain
Identity
15.4.3. Genetic
Stability
15.4.4. Purity
Testing
15.4.5. Use
Testing
15.5. Middle
East and Africa Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts,
By End User
15.5.1. Pharmaceutical
and Biotechnology Companies
15.5.2. Research
Institutions
15.5.3. Others
15.6. Middle
East and Africa Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Microbial Cell Line
15.6.1.1.1. Master Cell Bank (MCB)
15.6.1.1.2. Working Cell Bank (WCB)
15.6.1.1.3. End of Product Cells (EOPC)
15.6.1.1.4. Others
15.6.1.2. Saudi Arabia Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Species
15.6.1.2.1. Bacteria
15.6.1.2.2. Viruses
15.6.1.2.3. Cell Lines
15.6.1.2.4. Fungi and Yeast
15.6.1.2.5. Others
15.6.1.3. Saudi Arabia Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Testing Type
15.6.1.3.1. Culture Viability
15.6.1.3.2. Strain Identity
15.6.1.3.3. Genetic Stability
15.6.1.3.4. Purity Testing
15.6.1.3.5. Use Testing
15.6.1.4. Saudi Arabia Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By End User
15.6.1.4.1. Pharmaceutical and Biotechnology Companies
15.6.1.4.2. Research Institutions
15.6.1.4.3. Others
15.6.2. UAE
15.6.2.1. UAE Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
15.6.2.1.1. Master Cell Bank (MCB)
15.6.2.1.2. Working Cell Bank (WCB)
15.6.2.1.3. End of Product Cells (EOPC)
15.6.2.1.4. Others
15.6.2.2. UAE Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
15.6.2.2.1. Bacteria
15.6.2.2.2. Viruses
15.6.2.2.3. Cell Lines
15.6.2.2.4. Fungi and Yeast
15.6.2.2.5. Others
15.6.2.3. UAE Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
15.6.2.3.1. Culture Viability
15.6.2.3.2. Strain Identity
15.6.2.3.3. Genetic Stability
15.6.2.3.4. Purity Testing
15.6.2.3.5. Use Testing
15.6.2.4. UAE Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
15.6.2.4.1. Pharmaceutical and Biotechnology Companies
15.6.2.4.2. Research Institutions
15.6.2.4.3. Others
15.6.3. Egypt
15.6.3.1. Egypt Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
15.6.3.1.1. Master Cell Bank (MCB)
15.6.3.1.2. Working Cell Bank (WCB)
15.6.3.1.3. End of Product Cells (EOPC)
15.6.3.1.4. Others
15.6.3.2. Egypt Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
15.6.3.2.1. Bacteria
15.6.3.2.2. Viruses
15.6.3.2.3. Cell Lines
15.6.3.2.4. Fungi and Yeast
15.6.3.2.5. Others
15.6.3.3. Egypt Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
15.6.3.3.1. Culture Viability
15.6.3.3.2. Strain Identity
15.6.3.3.3. Genetic Stability
15.6.3.3.4. Purity Testing
15.6.3.3.5. Use Testing
15.6.3.4. Egypt Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
15.6.3.4.1. Pharmaceutical and Biotechnology Companies
15.6.3.4.2. Research Institutions
15.6.3.4.3. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
15.6.4.1.1. Master Cell Bank (MCB)
15.6.4.1.2. Working Cell Bank (WCB)
15.6.4.1.3. End of Product Cells (EOPC)
15.6.4.1.4. Others
15.6.4.2. Kuwait Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
15.6.4.2.1. Bacteria
15.6.4.2.2. Viruses
15.6.4.2.3. Cell Lines
15.6.4.2.4. Fungi and Yeast
15.6.4.2.5. Others
15.6.4.3. Kuwait Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
15.6.4.3.1. Culture Viability
15.6.4.3.2. Strain Identity
15.6.4.3.3. Genetic Stability
15.6.4.3.4. Purity Testing
15.6.4.3.5. Use Testing
15.6.4.4. Kuwait Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
15.6.4.4.1. Pharmaceutical and Biotechnology Companies
15.6.4.4.2. Research Institutions
15.6.4.4.3. Others
15.6.5. South
Africa
15.6.5.1. South Africa Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Microbial Cell Line
15.6.5.1.1. Master Cell Bank (MCB)
15.6.5.1.2. Working Cell Bank (WCB)
15.6.5.1.3. End of Product Cells (EOPC)
15.6.5.1.4. Others
15.6.5.2. South Africa Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Species
15.6.5.2.1. Bacteria
15.6.5.2.2. Viruses
15.6.5.2.3. Cell Lines
15.6.5.2.4. Fungi and Yeast
15.6.5.2.5. Others
15.6.5.3. South Africa Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Testing Type
15.6.5.3.1. Culture Viability
15.6.5.3.2. Strain Identity
15.6.5.3.3. Genetic Stability
15.6.5.3.4. Purity Testing
15.6.5.3.5. Use Testing
15.6.5.4. South Africa Microbial Cell Banking Market Revenue (US$ Mn)
and Forecasts, By End User
15.6.5.4.1. Pharmaceutical and Biotechnology Companies
15.6.5.4.2. Research Institutions
15.6.5.4.3. Others
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Microbial Cell Banking Market
Revenue (US$ Mn) and Forecasts, By Microbial Cell Line
15.6.6.1.1. Master Cell Bank (MCB)
15.6.6.1.2. Working Cell Bank (WCB)
15.6.6.1.3. End of Product Cells (EOPC)
15.6.6.1.4. Others
15.6.6.2. Rest of Middle East & Africa Microbial Cell Banking Market
Revenue (US$ Mn) and Forecasts, By Species
15.6.6.2.1. Bacteria
15.6.6.2.2. Viruses
15.6.6.2.3. Cell Lines
15.6.6.2.4. Fungi and Yeast
15.6.6.2.5. Others
15.6.6.3. Rest of Middle East & Africa Microbial Cell Banking Market
Revenue (US$ Mn) and Forecasts, By Testing Type
15.6.6.3.1. Culture Viability
15.6.6.3.2. Strain Identity
15.6.6.3.3. Genetic Stability
15.6.6.3.4. Purity Testing
15.6.6.3.5. Use Testing
15.6.6.4. Rest of Middle East & Africa Microbial Cell Banking Market
Revenue (US$ Mn) and Forecasts, By End User
15.6.6.4.1. Pharmaceutical and Biotechnology Companies
15.6.6.4.2. Research Institutions
15.6.6.4.3. Others
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By
Microbial Cell Line
15.7.3. By
Species
15.7.4. By
Testing Type
15.7.5. By End
User
16. Latin America Microbial Cell Banking Market Analysis and
Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Latin
America Microbial Cell Banking Market Revenue (US$ Mn)
16.2. Latin
America Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Microbial Cell Line
16.2.1. Master
Cell Bank (MCB)
16.2.2. Working
Cell Bank (WCB)
16.2.3. End of
Product Cells (EOPC)
16.2.4. Others
16.3. Latin
America Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Species
16.3.1. Bacteria
16.3.2. Viruses
16.3.3. Cell
Lines
16.3.4. Fungi
and Yeast
16.3.5. Others
16.4. Latin
America Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By Testing
Type
16.4.1. Culture
Viability
16.4.2. Strain
Identity
16.4.3. Genetic
Stability
16.4.4. Purity
Testing
16.4.5. Use
Testing
16.5. Latin
America Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By End
User
16.5.1. Pharmaceutical
and Biotechnology Companies
16.5.2. Research
Institutions
16.5.3. Others
16.6. Latin
America Microbial Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Country
16.6.1. Brazil
16.6.1.1. Brazil Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
16.6.1.1.1. Master Cell Bank (MCB)
16.6.1.1.2. Working Cell Bank (WCB)
16.6.1.1.3. End of Product Cells (EOPC)
16.6.1.1.4. Others
16.6.1.2. Brazil Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
16.6.1.2.1. Bacteria
16.6.1.2.2. Viruses
16.6.1.2.3. Cell Lines
16.6.1.2.4. Fungi and Yeast
16.6.1.2.5. Others
16.6.1.3. Brazil Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
16.6.1.3.1. Culture Viability
16.6.1.3.2. Strain Identity
16.6.1.3.3. Genetic Stability
16.6.1.3.4. Purity Testing
16.6.1.3.5. Use Testing
16.6.1.4. Brazil Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
16.6.1.4.1. Pharmaceutical and Biotechnology Companies
16.6.1.4.2. Research Institutions
16.6.1.4.3. Others
16.6.2. Argentina
16.6.2.1. Argentina Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Microbial Cell Line
16.6.2.1.1. Master Cell Bank (MCB)
16.6.2.1.2. Working Cell Bank (WCB)
16.6.2.1.3. End of Product Cells (EOPC)
16.6.2.1.4. Others
16.6.2.2. Argentina Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Species
16.6.2.2.1. Bacteria
16.6.2.2.2. Viruses
16.6.2.2.3. Cell Lines
16.6.2.2.4. Fungi and Yeast
16.6.2.2.5. Others
16.6.2.3. Argentina Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Testing Type
16.6.2.3.1. Culture Viability
16.6.2.3.2. Strain Identity
16.6.2.3.3. Genetic Stability
16.6.2.3.4. Purity Testing
16.6.2.3.5. Use Testing
16.6.2.4. Argentina Microbial Cell Banking Market Revenue (US$ Mn) and
Forecasts, By End User
16.6.2.4.1. Pharmaceutical and Biotechnology Companies
16.6.2.4.2. Research Institutions
16.6.2.4.3. Others
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Microbial Cell Banking Market Revenue
(US$ Mn) and Forecasts, By Microbial Cell Line
16.6.3.1.1. Master Cell Bank (MCB)
16.6.3.1.2. Working Cell Bank (WCB)
16.6.3.1.3. End of Product Cells (EOPC)
16.6.3.1.4. Others
16.6.3.2. Rest of Latin America Microbial Cell Banking Market Revenue
(US$ Mn) and Forecasts, By Species
16.6.3.2.1. Bacteria
16.6.3.2.2. Viruses
16.6.3.2.3. Cell Lines
16.6.3.2.4. Fungi and Yeast
16.6.3.2.5. Others
16.6.3.3. Rest of Latin America Microbial Cell Banking Market Revenue
(US$ Mn) and Forecasts, By Testing Type
16.6.3.3.1. Culture Viability
16.6.3.3.2. Strain Identity
16.6.3.3.3. Genetic Stability
16.6.3.3.4. Purity Testing
16.6.3.3.5. Use Testing
16.6.3.4. Rest of Latin America Microbial Cell Banking Market Revenue
(US$ Mn) and Forecasts, By End User
16.6.3.4.1. Pharmaceutical and Biotechnology Companies
16.6.3.4.2. Research Institutions
16.6.3.4.3. Others
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Microbial Cell Line
16.7.3. By
Species
16.7.4. By
Testing Type
16.7.5. By End
User
17. Competitive Benchmarking
17.1. Market
Share Analysis, 2020
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player Profiles
18.1. Ajinomoto
Bio-Pharma
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. Altogen
Labs
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business
Strategies
18.3. ATCC
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. Biovian
Oy
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. Charles
River Laboratories
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. Creative
Biogene
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. Eurofins
Scientific
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. Lonza
Group Ltd.
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. Luina Bio
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Merck
KGaA
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business
Strategies
18.11. Molecular
Diagnostic Services, Inc.
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business
Strategies
18.12. VGXI,
Inc.
18.12.1. Company
Details
18.12.2. Company
Overview
18.12.3. Product
Offerings
18.12.4. Key
Developments
18.12.5. Financial
Analysis
18.12.6. SWOT
Analysis
18.12.7. Business
Strategies
18.13. Vibalogics
GmbH
18.13.1. Company
Details
18.13.2. Company
Overview
18.13.3. Product
Offerings
18.13.4. Key
Developments
18.13.5. Financial
Analysis
18.13.6. SWOT
Analysis
18.13.7. Business Strategies
18.14. Other
Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
